Sequel Med Tech announced their commercial development agreement to integrate Sequel’s twiist Automated Insulin Delivery, AID, System powered by Tidepool with Senseonics (SENS)’ Eversense 365 CGM. Through this collaboration, the twiist AID System will become the first AID system compatible with the Senseonics Eversense 365, the world’s first and only one-year CGM system, offering people with type 1 diabetes a new level of flexibility and personalization in their diabetes management. The agreement between Sequel and Senseonics will provide individuals with type 1 diabetes the option of a one-year CGM that integrates with the twiist AID System. The integrated system aims to enhance diabetes management by offering people with diabetes more tools to manage care, which may lead to improved glucose control, increase convenience, and provide greater flexibility.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SENS:
- Positive Outlook for Senseonics Holdings: Buy Rating Backed by Unique iCGM Features and Market Expansion
- Senseonics initiated with an Outperform at Mizuho
- Senseonics Holdings: Strong Growth Potential with Eversense 365 and Strategic Partnerships
- Senseonics Earnings Call: Eversense 365 Shines Amid Challenges
- Senseonics Reports Growth and Eversense 365 Launch
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue